225 related articles for article (PubMed ID: 24906866)
1. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.
Martin K; Müller P; Schreiner J; Prince SS; Lardinois D; Heinzelmann-Schwarz VA; Thommen DS; Zippelius A
Cancer Immunol Immunother; 2014 Sep; 63(9):925-38. PubMed ID: 24906866
[TBL] [Abstract][Full Text] [Related]
2. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.
Müller P; Martin K; Theurich S; Schreiner J; Savic S; Terszowski G; Lardinois D; Heinzelmann-Schwarz VA; Schlaak M; Kvasnicka HM; Spagnoli G; Dirnhofer S; Speiser DE; von Bergwelt-Baildon M; Zippelius A
Cancer Immunol Res; 2014 Aug; 2(8):741-55. PubMed ID: 24916470
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
4. Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site.
Venghateri JB; Gupta TK; Verma PJ; Kunwar A; Panda D
PLoS One; 2013; 8(10):e75182. PubMed ID: 24124473
[TBL] [Abstract][Full Text] [Related]
5. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
Pai CS; Huang JT; Lu X; Simons DM; Park C; Chang A; Tamaki W; Liu E; Roybal KT; Seagal J; Chen M; Hagihara K; Wei XX; DuPage M; Kwek SS; Oh DY; Daud A; Tsai KK; Wu C; Zhang L; Fasso M; Sachidanandam R; Jayaprakash A; Lin I; Casbon AJ; Kinsbury GA; Fong L
Immunity; 2019 Feb; 50(2):477-492.e8. PubMed ID: 30737146
[TBL] [Abstract][Full Text] [Related]
6. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib Exerts
Ocadlikova D; Lecciso M; Broto JM; Scotlandi K; Cavo M; Curti A; Palmerini E
Front Immunol; 2021; 12():577766. PubMed ID: 33717062
[TBL] [Abstract][Full Text] [Related]
10. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
11. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
[TBL] [Abstract][Full Text] [Related]
12. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
13. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha.
Zhang W; Chen Z; Li F; Kamencic H; Juurlink B; Gordon JR; Xiang J
Immunology; 2003 Feb; 108(2):177-88. PubMed ID: 12562326
[TBL] [Abstract][Full Text] [Related]
14. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
[TBL] [Abstract][Full Text] [Related]
15. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
16. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell gene therapy.
Onaitis M; Kalady MF; Pruitt S; Tyler DS
Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
[TBL] [Abstract][Full Text] [Related]
18. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
19. β-glucan from Aureobasidium pullulans augments the anti-tumor immune responses through activated tumor-associated dendritic cells.
Shui Y; Hu X; Hirano H; Kusano K; Tsukamoto H; Li M; Hasumi K; Guo WZ; Li XK
Int Immunopharmacol; 2021 Dec; 101(Pt A):108265. PubMed ID: 34715491
[TBL] [Abstract][Full Text] [Related]
20. Ascophyllan functions as an adjuvant to promote anti-cancer effect by dendritic cell activation.
Zhang W; Okimura T; Xu L; Zhang L; Oda T; Kwak M; Yu Q; Jin JO
Oncotarget; 2016 Apr; 7(15):19284-98. PubMed ID: 27008707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]